Decreased expression of EZH2 reactivates RASSF2A by reversal of promoter methylation in breast cancer cells (Q38756890)

6 September 2017

title

Decreased expression of EZH2 reactivates RASSF2A by reversal of promoter methylation in breast cancer cells (English)

1 reference

6 September 2017

Pan Yu

1

1 reference

6 September 2017

Yawen Guo

2

1 reference

6 September 2017

Maimaiti Yusufu

3

1 reference

6 September 2017

Zeming Liu

4

1 reference

6 September 2017

Shan Wang

5

1 reference

6 September 2017

Xingjie Yin

6

1 reference

6 September 2017

Gongling Peng

7

1 reference

6 September 2017

Longqiang Wang

8

1 reference

6 September 2017

Xiangwang Zhao

9

1 reference

6 September 2017

Hui Guo

10

1 reference

6 September 2017

Tao Huang

11

1 reference

6 September 2017

Chunping Liu

12

1 reference

6 September 2017

publication date

20 July 2016

1 reference

Cell Biology International

6 September 2017

published in

1 reference

6 September 2017

volume

40

1 reference

6 September 2017

issue

10

1 reference

6 September 2017

page(s)

1062-1070

1 reference

The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer

6 September 2017

cites work

1 reference

Upregulation of DNA methyltransferase-mediated gene silencing, anchorage-independent growth, and migration of colon cancer cells by interleukin-6.

21 January 2018

1 reference

RASSF1A: Not a prototypical Ras effector.

21 January 2018

1 reference

RASSF2 hypermethylation is present and related to shorter survival in squamous cervical cancer.

21 January 2018

1 reference

CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations.

21 January 2018

1 reference

Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation

21 January 2018

1 reference

EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells

21 January 2018

1 reference

Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.

21 January 2018

1 reference

RASSF6 exhibits promoter hypermethylation in metastatic melanoma and inhibits invasion in melanoma cells

21 January 2018

1 reference

DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.

21 January 2018

1 reference

Targeting of cancer stem cells by inhibitors of DNA and histone methylation.

21 January 2018

1 reference

Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation

21 January 2018

1 reference

The murine polycomb group protein Eed is required for global histone H3 lysine-27 methylation

21 January 2018

1 reference

Chromatin regulator PRC2 is a key regulator of epigenetic plasticity in glioblastoma

21 January 2018

1 reference

DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression

21 January 2018

1 reference

De novo DNA methyltransferases Dnmt3a and Dnmt3b primarily mediate the cytotoxic effect of 5-aza-2'-deoxycytidine.

21 January 2018

1 reference

Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers

21 January 2018

1 reference

Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity

21 January 2018

1 reference

EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.

21 January 2018

1 reference

Promoter methylation status of Ras-association domain family members in pheochromocytoma

21 January 2018

1 reference

Roles of the EZH2 histone methyltransferase in cancer epigenetics

21 January 2018

1 reference

Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells

21 January 2018

1 reference

Analysis of the antiproliferative effects of 3-deazaneoplanocin A in combination with standard anticancer agents in rhabdoid tumor cell lines

21 January 2018

1 reference

The polycomb group protein EZH2 is involved in progression of prostate cancer

21 January 2018

1 reference

The Polycomb group protein EZH2 directly controls DNA methylation

21 January 2018

1 reference

The control of histone lysine methylation in epigenetic regulation

21 January 2018

1 reference

RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor

21 January 2018

1 reference

MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1

21 January 2018

1 reference

Cytochrome b5 reductase 2 is a novel candidate tumor suppressor gene frequently inactivated by promoter hypermethylation in human nasopharyngeal carcinoma

21 January 2018

1 reference

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.

21 January 2018

1 reference

Epigenetic therapy of cancer: past, present and future

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/CBIN.10646

1 reference

6 September 2017

1 reference